Resistance to BRAF inhibitors in BRAF V600E melanoma develops when secondary mutations and/or changes in basal protein expression allow for the activation of MEK/ERK signaling even in the presence of BRAF inhibitors [16,17,18,19]. Here, MAP2K7 is linked to melanoma.